Ironwood Pharmaceuticals 3Q 2016 Investor Update

Ironwood Pharmaceuticals presents third-quarter 2016 financial and operational updates, focusing on key product developments including linaclotide (LINZESS) and lesinurad. The presentation covers commercial performance, pipeline progress, anticipated regulatory milestones, and guidance for 2016 financial performance.